Ionis Pharmaceuticals Accounts Payable Over Time
| IONS Stock | USD 35.90 0.53 1.50% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Ionis Pharmaceuticals Performance and Ionis Pharmaceuticals Correlation. Ionis |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ionis Pharmaceuticals. If investors know Ionis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ionis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.44) | Earnings Share (2.44) | Revenue Per Share 5.503 | Quarterly Revenue Growth (0.07) | Return On Assets (0.07) |
The market value of Ionis Pharmaceuticals is measured differently than its book value, which is the value of Ionis that is recorded on the company's balance sheet. Investors also form their own opinion of Ionis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ionis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ionis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ionis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ionis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ionis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ionis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Accounts Payable Analysis
Compare Ionis Pharmaceuticals and related stocks such as Arrowhead Pharmaceuticals, Biomarin Pharmaceutical, and Incyte Accounts Payable Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARWR | 1.4 M | 878 K | 1.2 M | 2.6 M | 5 M | 12.2 M | 4.1 M | 2.8 M | 7.6 M | 6.8 M | 9.5 M | 2.9 M | 35.9 M | 11.4 M | 12 M |
| BMRN | 1.4 M | 12.2 M | 147.1 M | 95.3 M | 235.7 M | 392.5 M | 370.5 M | 401.9 M | 437.3 M | 570.6 M | 191.4 M | 193 M | 231.2 M | 315.5 M | 331.3 M |
| INCY | 500 K | 14.9 M | 14 M | 19.1 M | 24.5 M | 30.1 M | 75.6 M | 67.7 M | 103.8 M | 83.6 M | 98.8 M | 172.1 M | 277.5 M | 109.6 M | 115.1 M |
| APLS | 353.9 K | 353.9 K | 353.9 K | 353.9 K | 751.5 K | 2.5 M | 2.5 M | 3.7 M | 10.3 M | 8.4 M | 8.5 M | 16.9 M | 37.3 M | 37.5 M | 39.4 M |
| VKTX | 54 K | 54 K | 54 K | 74.1 K | 1.8 M | 592.4 K | 1.2 M | 1.5 M | 959 K | 2.4 M | 4 M | 1.4 M | 8.5 M | 7.5 M | 7.9 M |
| TERN | 914 K | 914 K | 914 K | 914 K | 914 K | 914 K | 914 K | 914 K | 914 K | 1.6 M | 935 K | 2.1 M | 1.6 M | 2.5 M | 1.8 M |
| AKRO | 60 K | 60 K | 60 K | 60 K | 60 K | 60 K | 60 K | 60 K | 1.4 M | 947 K | 3.4 M | 6.7 M | 8 M | 7 M | 4.3 M |
| ALNY | 674 K | 5.8 M | 4.4 M | 5.9 M | 15.1 M | 16.8 M | 54.5 M | 28.4 M | 59.7 M | 49.9 M | 52 M | 73.4 M | 98.1 M | 55.5 M | 28.9 M |
| EXEL | 3.6 M | 2 M | 4.4 M | 9.3 M | 6.4 M | 6.4 M | 6.6 M | 9.6 M | 10.9 M | 11.6 M | 23.6 M | 24.3 M | 32.7 M | 33.8 M | 35.5 M |
| HALO | 32.7 K | 7.6 M | 2.3 M | 3.1 M | 3 M | 4.5 M | 3.6 M | 7.9 M | 4.1 M | 6.4 M | 1.9 M | 1.5 M | 17.7 M | 11.8 M | 12.4 M |
| PTCT | 1.7 M | 1.9 M | 621.6 K | 1.1 M | 4.1 M | 11.9 M | 6.3 M | 15.3 M | 6 M | 10.3 M | 18.7 M | 23 M | 27.3 M | 6 M | 9.9 M |
| KRYS | 42 K | 42 K | 42 K | 42 K | 42 K | 42 K | 42 K | 193 K | 888 K | 724 K | 2.1 M | 8.4 M | 4 M | 1.8 M | 2.5 M |
| SRPT | 100 K | 9.4 M | 7.5 M | 17.6 M | 12.4 M | 20.2 M | 29.7 M | 8.5 M | 33.8 M | 68.1 M | 111.1 M | 76.7 M | 95.9 M | 164.9 M | 173.2 M |
| IOVA | 30.3 K | 190 K | 2.8 M | 1.1 M | 1.2 M | 958 K | 863 K | 1.2 M | 2.7 M | 15.6 M | 13.5 M | 27.4 M | 26.6 M | 33.1 M | 34.8 M |
| MDGL | 209 K | 3.5 M | 5.7 M | 6.6 M | 3.1 M | 1.3 M | 762 K | 1.9 M | 2.5 M | 1.2 M | 1 M | 21.4 M | 23.8 M | 28 M | 29.4 M |
Ionis Pharmaceuticals and related stocks such as Arrowhead Pharmaceuticals, Biomarin Pharmaceutical, and Incyte Accounts Payable description
An accounting item on the balance sheet that represents Ionis Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Ionis Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.My Equities
My Current Equities and Potential Positions
| Ionis Pharmaceuticals | IONS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 35.9
Additional Tools for Ionis Stock Analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.